Excerpt:
"WE read with great interest the article “A case for immunotherapy” (Sunday Star, Feb 12). Firstly, we would like to congratulate Chin (nasopharyngeal cancer) and Wong (prostate cancer) on improvements in their condition and for their successful struggle against cancer. Many like these two men are increasingly facing up to the reality of a cancer diagnosis as its prevalence rises in the Asia-Pacific region. However, upon reading the article we also noted several disturbing points regarding their treatment which we would like to highlight here.
Read more at http://www.thestar.com.my/opinion/letters/2017/03/03/clarifying-immunotherapy/#YZpc1jGgr7ttkogX.99
Link
"WE read with great interest the article “A case for immunotherapy” (Sunday Star, Feb 12). Firstly, we would like to congratulate Chin (nasopharyngeal cancer) and Wong (prostate cancer) on improvements in their condition and for their successful struggle against cancer. Many like these two men are increasingly facing up to the reality of a cancer diagnosis as its prevalence rises in the Asia-Pacific region. However, upon reading the article we also noted several disturbing points regarding their treatment which we would like to highlight here.
Firstly, immunotherapy is indeed emerging as a new and exciting breakthrough in our treatment armamentarium against cancer. Immunotherapy aims to harness or enhance the ability of our own immune system to recognise and mount an immune response against cancer cells. Indeed, over the past few years, several immune therapies such as PD-1 and PDL-1 checkpoint inhibitors have now received licensing approval from major health authorities such as the US Federal Drug Agency (FDA) and European Medicines Agency (EMA). Much time, cost and effort have gone into performing clinical trials involving thousands of patients in order to prove that these treatments are superior to current available treatments and can be safely given with acceptable side effects. Not least as these treatments are usually very costly, we need to be sure that they work before they are offered to the public.
In contrast, the HITV (Hasumi Immunotherapeutic Vaccine) treatment in combination with radiotherapy is not an FDA or EMA approved therapy. There are no large phase 2 or phase 3 clinical trials (such trials are a necessary requirement before new therapies can be approved by the regulatory authorities) that have been performed to prove that it works any better than conventional chemotherapy, radiotherapy or targeted therapy alone. Indeed, the clinical trials to explore whether cellular immunotherapy treatment such as HITV are effective are currently only in an initial stage of development and it is premature to suggest that these treatments should be offered widely to the public."
Read more at http://www.thestar.com.my/opinion/letters/2017/03/03/clarifying-immunotherapy/#YZpc1jGgr7ttkogX.99
No comments:
Post a Comment